| INTRODUCTION
Proteinuria is both a contributor to and a complication of chronic kidney disease (CKD), and it is associated with progression of disease and decreased survival in dogs and cats with kidney disease. 1, 2 Whereas dietary protein restriction is not recommended for early stages of CKD, reducing dietary protein is almost invariably recommended in nonazotemic proteinuric dogs to decrease proteinuria. [3] [4] [5] [6] Therefore, dogs with proteinuria are particularly predisposed to malnutrition, and optimal methods of nutritional management specific for this form of renal disease are needed. In people, both proteinuria and the inflammation associated with chronic disease can contribute to protein-energy wasting (PEW), resulting in accelerated loss of lean body mass that can also adversely affect morbidity and mortality. 7 Amino acid (AA) profiles are altered in dogs, cats, and humans with CKD. [8] [9] [10] Nonessential amino acids (NEAA) increase while essential amino acids (EAA) decrease in CKD, as compared to healthy control subjects. [10] [11] [12] Without adequate concentrations of EAA, animals cannot meet physiologic demands for protein synthesis, thus contributing to decreased albumin concentrations, impaired immune function, and loss of lean muscle mass. In addition to measuring absolute plasma concentrations, ratios comparing EAA and NEAA have been used in people to assess AA status. 12, 13 The alterations in AA in CKD are because of alterations in nitrogen metabolism, tubular filtration, reabsorption, and excretion as well as increased inflammation. 12, 14 Information on AA status in dogs with protein-losing nephropathy (PLN) is lacking in the literature, yet it might impact optimal management of dogs with PLN. The goal of our study was to characterize plasma AA profiles in dogs with PLN. We hypothesize that dogs with PLN will have altered plasma AA profiles as compared to healthy dogs. Dogs enrolled as controls were deemed healthy on the basis of a physical examination, CBC, serum biochemistry profile, and urinalysis.
The OSU-VMC Institutional Animal Care and Use Committee approved the protocol, and all owners signed a consent form before dogs were enrolled in the study.
| Study design
Each dog had a physical examination performed, including body weight, body condition score (BCS; on a 1-9 scoring system) and muscle condition score (MCS; using normal, mild, moderate, or severe scores). 15 All BCS and MCS scoring were done by 1 author (V. J. Parker). A Doppler systolic blood pressure was measured. Blood was collected via jugular venipuncture and urine was collected via cystocentesis for CBC, serum biochemistry profile, urinalysis, urine culture, and UPC.
Heparinized plasma was collected for AA analysis. After collection, the plasma was mixed in a 1 : 1 ratio with 6% sulfasalicylic acid and sat for 20 minutes. This mixture was then centrifuged at 14 000 rpm 
| AA analysis
Plasma AA concentrations were measured with an automated highperformance liquid chromatography AA analyzer (Biochrom 30; Biochrom Ltd, Holliston, Massachusetts) using a method described elsewhere (Kim 1995) . 16 
| Data analysis
The nonparametric Wilcoxon rank sum test was used to compare the AA profiles of PLN and control dogs. The Holm-Bonferroni method was used to control the type I error at a familywise rate of 5%. Data are presented as median and range. P-values <.05 were considered significant. Sums of EAA and NEAA were calculated.
Ratios of EAA-to-NEAA, valine-to-glycine, tyrosine-to-phenylalanine, and glycine-to-serine were compared between PLN and control dogs.
Statistical analysis was performed using R 3. Pertinent laboratory values from the PLN and control cohorts are presented in Table 1 . According to the IRIS CKD staging system, dogs were classified as stage 1 (n = 23), stage 2 (n = 1), stage 3 (n = 6).
Median UPC was 4.8 (range, 1.7-27.5). Eleven PLN dogs had hypoalbuminemia (<2.9 g/dL), and the median UPC of these dogs was 7.1 (range, 4.2-27.5). None of the control dogs was proteinuric or hypoalbuminemic. One dog had an increased systolic blood pressure of 180 mm Hg. No specific underlying etiology was determined to account for this canine hypertension.
All PLN dogs were eating commercial diets with a wide range of dietary protein concentrations. Only 4 dogs were eating a diet specifically designed for dogs with kidney disease. Eighteen dogs were receiving medications to inhibit the renin-angiotensin-aldosterone system.
Eight dogs were receiving fish oil supplements. Five dogs were also receiving glucosamine/chondroitin.
| AA profiles
Results of complete AA profiles are in Table 2 Similar to what has been described in other studies of human CKD, dogs with PLN had significantly lower leucine, tyrosine, and threonine concentrations, as compared to healthy controls. 11, 12 However, there were several dissimilarities between our findings and these studies, as well as people with nephrotic syndrome in which there are significantly higher concentrations of NEAA, glutamic acid, hydroxyproline and alanine. 13 In people with CKD, low histidine concentrations are associated with PEW, inflammation, oxidative stress, and decreased survival.
18
The kidneys express the enzyme phenylalanine hydroxylase which is responsible for conversion of phenylalanine to tyrosine. 19 Decreased expression of this enzyme likely explains our finding of lower plasma tyrosine concentration and tyrosine-to-phenylalanine ratio in the dogs with PLN. For this reason, tyrosine has been proposed to be a conditionally EAA in people with kidney disease. 19 Other AA ratios that have been described to have clinical importance in humans with kidney disease are glycine : serine and valine :
glycine. Both these ratios correlate with glomerular filtration rate (GFR) in humans. 20 The glycine : serine ratio increases and the valine :
glycine ratio decreases as GFR decreases. 20 Because the kidney is a major site for conversion of glycine to serine, it is not unexpected that dogs with kidney disease can have both higher glycine concentrations and glycine : serine ratios. 20 However, we found the dogs with PLN in this study had lower plasma glycine concentrations and glycine : serine ratios than the control dogs. This might be due in part to an effect of age as glycine concentrations have been shown to decrease with age in dogs. 21 In humans with CKD, plasma valine concentrations and the valine :
glycine ratio decrease with more advanced CKD. improve protein status while minimizing nitrogen load. 23, 24 This concept is related to the ability of keto acids to stimulate protein synthesis while inhibiting protein breakdown. This diet regimen improves hypoalbuminemia and reduces proteinuria. 23 Additionally, in 1 study in humans with CKD, those who received an AA supplement had lower C-reactive protein concentrations than those who did not. 18 Oral EAA supplementation for 4-8 weeks in dogs with renal proteinuria results in increased serum albumin concentrations and body The whiskers extend up to 1.5× IQR below and above the 25th and 75th percentiles, respectively. Points above and below the whiskers are indications for outlier values. The dogs with PLN had lower glycine-to-serine (P < .05) and tyrosine-to-phenylalanine ratios (P < .05 and P < 0.01, respectively) and higher valine-to-glycine ratios (P < .001). IQR, interquartile range; PLN, protein-losing nephropathy weight with no effect on UPC. 25 Ultimately, it remains unclear whether the lack of decrease in UPC is clinically as important as the increase in albumin and body weight.
There were a few limitations to note. The study population was not a totally homogenous group, and renal biopsy was not performed to specifically identify type of kidney disease present. We initially set out to include dogs only with stage 1 and 2 CKD to reduce the effect that more advanced azotemia might have on AA status, as cats with CKD had more pronounced AA alterations with disease progression; 9 however, given timing of dog recruitment, some dogs with stage 3 CKD were enrolled.
Many dogs did have abdominal ultrasound examinations performed, but dogs were not required to have this test performed.
Although specific infectious disease testing was not required, there is anecdotally a low rate of tick-borne infections seen at this teaching hospital. Unfortunately, not all dogs were fasted before sample collection, which might influence AA concentrations. None of the samples were noted to be overtly hemolyzed.
The PLN dogs did differ in age and size from the control dogs, which might bias results. We did not see significant evidence of relationship between AA levels and age or weight; nevertheless, the assumption for the absence of relationship between the AA and age and weight is needed. One study that compared plasma AA from 19 different breeds (not specified) revealed that plasma AA did change from birth to young adulthood (1-5 years), but changes were variable, and dogs >5 years were not assessed. 21 In conclusion, we found that dogs with PLN have altered AA status as compared to healthy control dogs. It remains to be determined whether these findings correlate with disease progression, PEW, or survival.
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